BioNTech Completes Minimum Acceptance Criteria for CureVac Share Exchange Offer

BioNTech has fulfilled the minimum acceptance requirements for the exchange offer for CureVac shares, with 184.071.410 CureVac shares, or 81.74% of the outstanding shares, tendered before the original offer deadline. The offer's acceptance period has begun and will end on December 18, 2025. Non-tendering CureVac shareholders will receive BioNTech ADSs or bar exchange payments after the completion of the post-offer reorganization, which may be subject to Dutch dividend withholding tax.